BIMETALLIC COMPLEXES FOR POTENTIAL PHOTOCHEMOTHERAPY
用于潜在光化学治疗的双金属配合物
基本信息
- 批准号:6498888
- 负责人:
- 金额:$ 17.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-02-01 至 2006-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Adapted from applicant's abstract) The proposed research focuses
on the use of ligand-bridged neutral and cationic d7-d7 and d8-d8 bimetallic
metal complexes for photochemotherapy. Initiation of anti-tumor drug activity
utilizing light has been an area of intense research with mixed success. The
systems previously chosen for these studies have typically been fluorescent
singlet excited states of organic molecules, their respective triplet states,
or luminescent inorganic complexes. Problems encountered include short excited
state lifetimes, high energy ultraviolet photons necessary for excitation, and
the reaction of the photogenerated intermediates at undesired sites. A new
avenue of research can be opened with the investigation of the non- or
weakly-emissive excited states of mononuclear and bimetallic complexes, whose
photophysical properties and reactivity remain largely unexplored.
The potential advantages of these systems presented here include their
increased redox reactivity through the presence of the metal center, their
ability to be excited with visible light (lambda > 600 nm), and the ease with
which they can be chemically modified to permit binding at selective DNA sites
and to improve the excited state properties. Bimetallic systems that can be
photoexcited with visible light to afford a reactive diradical excited state
that can act as inorganic enediyne analogs, and whose reaction can be
photoactivated. All of the molecules currently utilized in photodynamic therapy
require oxygen for their activity since the excited states themselves are not
reactive, therefore when the oxygen supply is depleted their reactivity is shut
down. Our preliminary results show that the d7-d7 (RhII)2 systems can
photocleave DNA effectively through the formation of singlet oxygen, however,
the excited states themselves can photocleave duplex DNA. In addition to
various dirhodium(II) complexes, we will also explore the excited state
reactivity and DNA photocleavage by cationic d7-d7 (PtIII)2 and neutral d8-d8
(PtII)2 Systems
描述:(改编自申请人摘要)拟议的研究重点
关于使用配体桥连的中性和阳离子D7-D7和D8-D8
用于光化学疗法的金属络合物。抗肿瘤药物活性的起始
利用光是一个密集研究的领域,其成功与否参差不齐。的
以前为这些研究选择的系统通常是荧光的
有机分子的单重激发态,它们各自的三重态,
或发光无机复合物。遇到的问题包括短激励
状态寿命,激发所需的高能紫外光子,以及
光生中间体在不需要的位点的反应。一个新
通过对非或非现象的调查,可以开辟研究的途径
单核和单核络合物的弱发射激发态,
生物物理性质和反应性仍然在很大程度上未被探索。
本文介绍的这些系统的潜在优势包括:
通过金属中心的存在增加氧化还原反应性,
能够被可见光(λ> 600 nm)激发,并且易于
它们可以被化学修饰以允许在选择性DNA位点结合
并改善激发态性质。双金属系统,
用可见光光激发以提供反应性双自由基激发态
其可以作为无机烯二炔类似物,并且其反应可以
光活化的目前用于光动力疗法的所有分子
因为激发态本身不需要氧,
反应性,因此当氧气供应耗尽时,它们的反应性被关闭
下来我们的初步结果表明,d7-d7(RhII)2系统可以
通过单线态氧的形成有效地光切割DNA,然而,
激发态本身可以光切割双链体DNA。除了
各种dirhodium(II)配合物,我们也将探索激发态
阳离子d7-d7(PtIII)2和中性d8-d8的反应性和DNA光切割
(PtII)2系统
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Claudia Turro其他文献
Claudia Turro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Claudia Turro', 18)}}的其他基金
BIMETALLIC COMPLEXES FOR POTENTIAL PHOTOCHEMOTHERAPY
用于潜在光化学治疗的双金属配合物
- 批准号:
6227377 - 财政年份:2001
- 资助金额:
$ 17.86万 - 项目类别:
BIMETALLIC COMPLEXES FOR POTENTIAL PHOTOCHEMOTHERAPY
用于潜在光化学治疗的双金属配合物
- 批准号:
6699025 - 财政年份:2001
- 资助金额:
$ 17.86万 - 项目类别:
BIMETALLIC COMPLEXES FOR POTENTIAL PHOTOCHEMOTHERAPY
用于潜在光化学治疗的双金属配合物
- 批准号:
6846859 - 财政年份:2001
- 资助金额:
$ 17.86万 - 项目类别:
BIMETALLIC COMPLEXES FOR POTENTIAL PHOTOCHEMOTHERAPY
用于潜在光化学治疗的双金属配合物
- 批准号:
6628958 - 财政年份:2001
- 资助金额:
$ 17.86万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 17.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 17.86万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 17.86万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 17.86万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 17.86万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 17.86万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 17.86万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 17.86万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 17.86万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 17.86万 - 项目类别: